Obesity Paradox in Non Valvular Atrial Fibrillation Regarding Outcomes: Fact or Fiction

August 3, 2022 updated by: Christena amir, Assiut University

Obesity Paradox in Non Valvular Atrial Fibrillation

Obesity paradox In patient with non valvular atrial fibrillation

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Study role of obesity in outcomes of anticoagulation in patients with non valvular atrial fibrillation

Study Type

Observational

Enrollment (Anticipated)

1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
      • Assiut, Egypt, 23123
        • Recruiting
        • Kristen amir
        • Contact:
          • Kristen Amir

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Obese patients with non valvular atrial fibrillation within one year from 1/6/2019 to 31/5/2020 among patients with non valvular in assuit university hospitals

Description

Inclusion Criteria:

  • patients presented with non valvular AF
  • patients on oral anticoagulant

Exclusion Criteria:

  • valvular AF
  • Mental illness
  • History of cerebrovascular stroke
  • history of bleeding tendency
  • history of Chronic renal failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Obese Patients with non valvular AF
Obese Patients with non valvular AF using oral anti coagulants
Drug: Oral Anticoagulant
Oral tablets of anti coagulations either warfare or NOACs

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between obesity and outcomes in non valvular atrial fibrillation
Time Frame: Sixth months
To study effect of obesity in outcomes of non valvular atrial fibrillation regarding the effect of obesity in the outcome of anticoagulants
Sixth months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2020

Primary Completion (Anticipated)

August 1, 2023

Study Completion (Anticipated)

October 1, 2023

Study Registration Dates

First Submitted

March 25, 2019

First Submitted That Met QC Criteria

April 3, 2019

First Posted (Actual)

April 5, 2019

Study Record Updates

Last Update Posted (Actual)

August 4, 2022

Last Update Submitted That Met QC Criteria

August 3, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Assuit35

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity Paradox

Clinical Trials on Oral Anticoagulant

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe